ClinicalTrials.gg
RecruitingNCT05148286ALCAMISTUpdated Jul 16, 2026

Albumin and Crystalloid Administration in Septic Shock

A Phase 4 interventional study of Treatment and Placebo in Septic Shock, sponsored by Asan Medical Center. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Asan Medical Center · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2022; still recruiting 4 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
2,426
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Shock, Septic with a site in Korea, Republic of — 2 open to participants now, 2 under way, none of them phase 3. Shock, Septic · Korea, Republic of.

Planned enrollment
Largest of 10
2,426 · median 165
Started
2022
the only one that year
Phase 4
2 of 11
1 open now
Registered
10th of 11
by date
Lead sponsor
2 of 11
Asan Medical Center

Among the 11 studies in Shock, Septic with a site in Korea, Republic of, this one has the largest planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 2 in phase 4, and was the 10th registered.

Shock, Septic

1,079 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

2 of the 11 studies in Shock, Septic with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 102 (74%) set no upper age limit and 19 (14%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Shock, Septic with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The current guideline emphasizes fluid resuscitation as the mainstay of initial management for septic shock. Albumin has the oncotic activity to maintain intravascular volumes with additional beneficial properties in sepsis. Prior studies showed that the replacement of albumin might have survival advantages in patients with septic shock. The investigators aim to assess whether the early administration of albumin with crystalloid as initial fluid resuscitation improves survival in patients with septic shock compared to resuscitation without albumin.

Read the detailed description

Sepsis is a leading cause of mortality worldwide, contributing to an estimated 11 million deaths in 2017-or 20% of all global deaths. Due to recent advances in the medical management and treatment of sepsis, the mortality of sepsis has been declined in these years, but still stayed at a high level. From 2004, the Surviving Sepsis Campaign (SSC) suggested a protocolized bundle therapy to facilitate implementation at the bedside with a defined target. Recent guideline states that this resuscitation bundle treatment should be initiated within 1 h of the emergency department (ED) triage time, named as 1-h bundle.

Fluid resuscitation, which is the mainstay of treatment to restore a patient's tissue perfusion, is associated with outcome in emergency department patients. The current guideline recommends that crystalloid for initial fluid resuscitation in sepsis and albumin can be additionally administered when patients require substantial amounts of crystalloid. Besides its oncotic functions to provide adequate intravascular volume, albumin has several beneficial properties for sepsis patients, including binding and transport of various endogenous molecules, anti-inflammatory and anti-oxidative effects, and modulation of nitric oxide metabolism. In 2004, a large randomized, prospective, double-blind study was performed in 7000 critically ill patients (SAFE study) to evaluate the effect of volume replacement therapy with human albumin on the outcome compared to only crystalloid. Although the survival rates were similar between the groups, a post hoc analysis of 1218 patients with severe sepsis showed improved survival in the albumin group compared to crystalloid alone. Furthermore, the ALBumin Italian Outcome Sepsis (ALBIOS) study investigated the effect of albumin administration and maintenance of serum albumin concentrations to at least 30 g/l on outcome in patients with severe sepsis and septic shock. This study showed a similar result to SAFE study that no difference on the outcome between the groups. Nevertheless, in the 1121 patients with septic shock, 90-day mortality was lower in the albumin group (564 patients) than in the non-albumin group (43.6 vs. 49%, p = 0.03). Recently, a retrospective study which evaluated the effect of administration of albumin combined with crystalloids in septic patients showed improved survival in 28 days. Therefore, accumulating evidence suggests that early albumin administration may provide a survival benefit in patients with severe and advanced sepsis. However, no prospective, randomized trial has adequately studied this hypothesis in patients with septic shock.

The aim of the ALCAMIST (ALbumin and Crystalloid AdMinistration In SepTic shock) study is to investigate the effect of albumin and crystalloid administration as an initial fluid choice in septic shock compared to crystalloid alone on patient survival.

03

Conditions studied

  • Septic Shock

Browse trials for

Keywords

  • Septic shock
  • Fluid resuscitation
  • Albumin
  • Crystalloid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (≥ 18 years) who visit an ED directly and are suspected of sepsis with shock
  • Shock is defined as hypotension (mean arterial blood pressure (MAP) \< 65 or systolic blood pressure \< 80) and tissue hypoperfusion such as an initial serum lactate level ≥ 4 mmol/dL.

Exclusion criteria

Exclusion Criteria:

  • patients who are transferred from another hospital after initial fluid administration
  • patients who have set limitations on treatment (e.g. patients with a signed do-not-resuscitate order)
  • patients with moribund conditions with less than 28 days due to secondary diseases or advanced malignant disease and palliative situations with life expectancy less than 6 months
  • patients who have been administered albumin before enrollment
  • patients who have known to albumin
  • Clinical conditions, where albumin administration may be unfavorable (e.g. pulmonary edema, congestive heart failure, traumatic brain injury)
  • lactation
  • patients who do not voluntarily consent to participate in the trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,426 participants (estimated)

Study arms

  • Active comparator
    Treatment

    For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1\~2h for initial fluid resuscitation.

    Drug: Treatment

  • Placebo comparator
    Control

    For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice.

    Drug: Placebo

Interventions

  • DrugTreatment

    For the treatment group, 200cc of 20% human albumin with 15 cc per kg of crystalloid will be administered over 1\~2h for initial fluid resuscitation. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.

    Also known as: Albumin and crystalloid

  • DrugPlacebo

    For the control group, 30 cc per kg of crystalloid will be administered according to the usual practice. The treating physicians can choose the type of fluid, such as balanced fluid or isotonic saline.

    Also known as: Crystalloid only

06

What researchers measure

Primary outcomes

  1. 28-day all-cause mortality

    The 28-day all-cause mortality in septic shock patient after admission will be evaluated

    Time frame: 28-days

Secondary outcomes

  1. 90-day all-cause mortality

    All-cause death within 90 days

    Time frame: 90 days

  2. ICU mortality

    All-cause death during ICU admission

    Time frame: 28 days

  3. Hospital mortality

    All-cause death during hospitalization

    Time frame: 28 days

  4. The Sequential organ Failure Assessment (SOFA) score

    The SOFA score will be recorded daily up to 28 days after randomization. Death within 72 hours will be counted as the maximum SOFA score.

    Time frame: 28 days

  5. Intensive Care Unit (ICU) stay

    The total length of ICU stay will be determined from the date of ICU admission until the patient is discharged from the ICU or the date of death from any cause, assessed up to 90 days after the first day of admission.

    Time frame: 90 days

  6. 7-day mortality

    All-cause death within 7 days

    Time frame: 7 days

  7. Ventilator free days

    Days without ventilator within 28 days from admission

    Time frame: 28 days

  8. Vasopressor free days

    Days without vasopressor within 28 days from admission

    Time frame: 28 days

  9. Total amount of fluid administration

    Total amount of fluid administration during hospital admission

    Time frame: 3 day, 7 day, 28 day

  10. Total fluid balance

    Fluid balance will be recorded daily up to 28 days after randomization

    Time frame: 28 days

  11. Maximum dose of vasopressor use

    Maximum dose of vasopressor during hospital admission

    Time frame: 28 days

  12. Renal replacement therapy

    Whether renal replacement therapy was initiated during hospital admission after randomization.

    Time frame: 28 days

  13. Safety-related parameters

    Occurrence of adverse event, serious adverse event (e.g. anaphylactic shock, hypervolemia, pulmonary edema)

    Time frame: 28 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Sep 2027, 68 months after the start.

Of 39 non-industry phase 4 interventional studies under Shock, Septic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 38. This study's planned 68 months is above that.

Counting every sponsor, half of 40 studies reached it within 24 months; a quarter within 16 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2021
First posted
Dec 8, 2021
StartActual
Jan 17, 2022
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05148286
Collaborators
Samsung Medical Center, Gangnam Severance Hospital, Chungnam National University Hospital, Seoul National University Hospital, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center, Hanyang University, Korea University Ansan Hospital
Responsible party
Won Young Kim (Professor, Asan Medical Center) — Principal investigator
First posted
Dec 8, 2021
Start date
Jan 17, 2022
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 16, 2026

Study contacts

Sang-Min Kim, Dr.
Contact
swdarkhorse@gmail.com
82-10-3010-0730
Won Young Kim, PhD
Contact
wonpia73@naver.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion